Capecitabine News and Research

RSS
Chemotherapy drug effective at preventing breast cancer's return, gives patients a better quality of life

Chemotherapy drug effective at preventing breast cancer's return, gives patients a better quality of life

Common heartburn medications could decrease effects of chemotherapy in cancer patients

Common heartburn medications could decrease effects of chemotherapy in cancer patients

Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

Study assesses effect of chemoradiotherapy on survival of locally advanced pancreatic cancer patients

Study assesses effect of chemoradiotherapy on survival of locally advanced pancreatic cancer patients

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

Gene expression analysis points metastatic CRC patient to successful irbesartan therapy

CTCA at Western announces launch of Phase II NivoPlus clinical trial

CTCA at Western announces launch of Phase II NivoPlus clinical trial

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

FDA approves Vistogard (uridine triacetate) for emergency treatment of chemotherapy overdose

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

Capecitabine increases disease-free survival for HER2-negative breast cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

CTCA at Western begins Phase Ib/II trial of new immunotherapy treatment for cancer patients

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Investigational anti-cancer agent ONT-380 shows activity against HER2+ breast cancer

Drug combination lengthens lives of metastatic colorectal cancer patients

Drug combination lengthens lives of metastatic colorectal cancer patients

Eribulin therapy effective in women with metastatic breast cancer

Eribulin therapy effective in women with metastatic breast cancer

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

Eribulin drug has minor added benefit in one patient group, indication of lesser benefit in others

NCCN ORP awards four research grants to advance development of nintedanib

NCCN ORP awards four research grants to advance development of nintedanib

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Mylan announces launch of Capecitabine Tablets USP, 150 mg and 500 mg

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast cancer patients

Teva launches generic Xeloda Tablets in the U.S.

Teva launches generic Xeloda Tablets in the U.S.

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Tumor-infiltrating lymphocytes may be good biomarker of response to trastuzumab in breast cancer

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

First generic version of Xeloda gets FDA approval for breast and colorectal cancers

First generic version of Xeloda gets FDA approval for breast and colorectal cancers